PT  - JOURNAL ARTICLE
AU  - Dyson, Louise
AU  - Hill, Edward M.
AU  - Moore, Sam
AU  - Curran-Sebastian, Jacob
AU  - Tildesley, Michael J.
AU  - Lythgoe, Katrina A
AU  - House, Thomas
AU  - Pellis, Lorenzo
AU  - Keeling, Matt J.
TI  - Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics
AID  - 10.1101/2021.06.07.21258476
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.07.21258476
4099  - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258476.short
4100  - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258476.full
AB  - Ongoing infection with, and associated viral reproduction of, SARS-CoV-2 provides opportunities for the virus to acquire advantageous mutations, which may alter viral transmissibility and disease severity, and allow escape from natural or vaccine-derived immunity. The number of countries reporting Variants of Concern (VOCs) with such mutations continues to rise. Here, we investigate two scenarios for third waves of the COVID pandemic: one driven by increased transmissibility, and another driven by immune escape. We do this using three mathematical models: a parsimonious susceptible-latent-infectious-recovered (SEIR) deterministic model with homogeneous mixing, an age-structured SARS-CoV-2 transmission model and a stochastic importation model. We calibrated our models to the situation in England in May 2021, although the insights will generalise to other contexts. We therefore accurately captured infection dynamics and vaccination rates, and also used these to explore the potential impact of a putative new VOC-targeted vaccine. Epidemiological trajectories for putative VOCs are wide-ranging and heavily dependent on their transmissibility, immune escape capability, and the time at which a postulated VOC-targeted vaccine may be introduced. We demonstrate that a VOC with either a substantial transmission advantage over resident variants, or the ability to evade vaccine-derived and prior immunity, is expected to generate a wave of infections and hospitalisations comparable to those seen in the winter 2020-21 wave. Moreover, a variant that is less transmissible, but shows partial immune-escape could provoke a wave of infection that would not be revealed until control measures are further relaxed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSM and MJK were supported by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical \& Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. LD, EMH, MJT and MJK were supported by the Medical Research Council through the COVID-19 Rapid Response Rolling Call [grant number MR/V009761/1]; LD, MJT and MJK were supported by the Engineering and Physical Sciences Research Council through the MathSys CDT [grant number EP/S022244/1]; KAL was supported by the Li Ka Shing Foundation; LP was supported by the Wellcome Trust and the Royal Society [grant number 202562/Z/16/Z]; TH was supported by the Royal Society [grant number INF/R2/180067]; TH and LP were also supported by the UK Research and Innovation COVID-19 rolling scheme [grant numbers EP/V027468/1 and MR/V028618/1] as well as the Alan Turing Institute for Data Science and Artificial Intelligence. LD, LP, TH, MJT and MJK were supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data utilised in this study are publicly available, with relevant references and data repositories stated within the main manuscript and Supporting Information. The code repository for the study is available at: https://github.com/LouiseDyson/COVID19-variants-of-concern-modelling-paper. https://github.com/LouiseDyson/COVID19-variants-of-concern-modelling-paper